If you’ve searched for apomorphine for ED, you’ve come across a medication with an unusual story — once positioned as a serious challenger to Viagra, withdrawn from the US market before it ever launched, and still prescribed sparingly in parts of Europe. Understanding why apomorphine fell short clarifies what actually works for erectile dysfunction in 2026, and where modern in-clinic options like intracavernosal botulinum toxin fit in.
Apomorphine (brand names Uprima and Ixense) is a sublingual dopamine agonist that triggers erection signaling in the brain. TAP Pharmaceuticals withdrew its US NDA in 2000 over hypotension and syncope concerns, and the drug was outclassed clinically and commercially by sildenafil. It remains available in some European markets but is rarely a first-line choice. For most men today, modern PDE5 inhibitors and newer in-clinic options like intracavernosal botulinum toxin offer better outcomes.
What is apomorphine?
Apomorphine is a non-selective dopamine receptor agonist — it activates dopamine D1 and D2 receptors in the brain.[1] The molecule has been used in medicine since the late 19th century, originally as an emetic and, more recently, in advanced Parkinson’s disease (where it’s given by subcutaneous injection or infusion).
In the 1990s, researchers found that low sublingual doses could trigger erections in men with erectile dysfunction by acting on the paraventricular nucleus of the hypothalamus — the brain region that initiates the neural cascade leading to erection.[2] This was a fundamentally different approach from sildenafil, which had launched in 1998 and worked by relaxing penile smooth muscle directly.
The sublingual ED formulation was developed under the brand names Uprima (US, by TAP Pharmaceuticals) and Ixense (Europe, by Abbott / Takeda).
The Uprima story: why apomorphine failed in the US
Uprima was supposed to be a major launch. TAP filed its New Drug Application with the FDA in 1999, expecting to compete head-to-head with Viagra. It never happened. In June 2000, after an FDA advisory committee raised concerns about severe hypotension and syncope in a small but real subset of patients, TAP voluntarily withdrew the NDA.[3] Sublingual apomorphine was never approved or marketed in the United States.
Europe took a different view. The EMA approved Uprima in May 2001 for mild-to-moderate ED.[4] By that point sildenafil had a massive head start, the efficacy gap was clear, and apomorphine never gained meaningful market share. Abbott discontinued Ixense in 2006. Uprima was eventually withdrawn from most European markets as well, though generic sublingual apomorphine is still produced and prescribed in select countries.
How apomorphine works — and why that mattered
Apomorphine and PDE5 inhibitors take fundamentally different routes to the same end point. Apomorphine acts centrally, in the brain. PDE5 inhibitors act peripherally, in the penis itself. Newer in-clinic options like UroFirm (intracavernosal botulinum toxin) also act peripherally, but on a different target — adrenergic tone in cavernosal smooth muscle.
paraventricular nucleus
smooth muscle
The central-action approach had a theoretical advantage: it didn’t require the downstream peripheral pathway to be fully intact. In practice it created two problems. First, you can’t dose central effects with the same precision — the same brainstem receptors driving the therapeutic effect also drove nausea and hypotension. Second, the response was modest. The drug worked, but not as reliably as sildenafil.
Apomorphine vs PDE5 inhibitors: efficacy
Across multiple controlled trials, sublingual apomorphine produced successful intercourse roughly 45–50% of the time at 3 mg, compared with placebo response rates around 30%.[5] Sildenafil 100 mg produced successful intercourse rates of 70–80% in similar populations.[6]
The gap was clinically meaningful. In direct comparisons, men preferred sildenafil for both efficacy and predictability. Apomorphine’s onset of action — about 18–20 minutes[5] — wasn’t appreciably faster than sildenafil’s, removing one of its theoretical advantages.
Side effects and safety
Apomorphine’s side effect profile was its other major problem. Nausea was the most common adverse event, reported by roughly 7% of patients at 3 mg, and as high as 20% at higher experimental doses.[5] Yawning, dizziness, headache, and somnolence were frequent. The most serious concern — the one that ultimately sank Uprima in the US — was a small but real incidence of vasovagal syncope: a sudden drop in blood pressure leading to fainting.[3]
| Apomorphine SL | Sildenafil | UroFirm (intracavernosal botulinum toxin) | |
|---|---|---|---|
| Mechanism | Central D1/D2 agonist | Peripheral PDE5 inhibitor | Peripheral neuromuscular — blocks norepinephrine release |
| Onset | 18–20 min | 30–60 min | Cumulative — effect builds over weeks |
| Duration per dose | ~2 hours | 4–5 hr (sildenafil); 24–36 hr (tadalafil) | 3–6 months per injection |
| Use pattern | On-demand | On-demand or daily | Continuous baseline improvement |
| Common side effects | Nausea, yawning, dizziness, syncope | Headache, flushing, nasal congestion | Mild bruising at injection site |
| Available in US | No | Yes | Yes (in-clinic) |
| Typical first-line use | Rare | Standard | Add-on / non-responders |
Is apomorphine still available?
In the United States, sublingual apomorphine for ED is not available. The Uprima NDA was withdrawn before approval and has not been resubmitted. Injectable apomorphine (Apokyn, Kynmobi) is approved for advanced Parkinson’s disease but is not used for ED.
In parts of Europe, generic sublingual apomorphine is still produced and prescribed, though use has declined sharply. Most European urology guidelines list it as a third- or fourth-line option after PDE5 inhibitors and intracavernosal therapy. Some online pharmacies advertise apomorphine internationally — caution is warranted, since products from unregulated sources can be misrepresented or counterfeit, and unsupervised use carries syncope risk.
What works better now
1. Modern PDE5 inhibitors
Sildenafil, tadalafil, vardenafil, and avanafil remain first-line. Tadalafil’s 24–36-hour duration[7] and availability in low daily doses (2.5–5 mg, FDA-approved 2008)[8] gave PDE5 therapy a flexibility apomorphine never matched. Generics have made these treatments inexpensive. For roughly 70% of men with mild-to-moderate ED, a properly dosed PDE5 inhibitor is sufficient.
2. Intracavernosal botulinum toxin (UroFirm)
For men whose response to oral medications is inadequate — or who want a treatment that works without requiring an on-demand pill — intracavernosal botulinum toxin has emerged as a meaningful in-clinic option. UroFirm uses small, precisely placed injections of botulinum toxin into the corpus cavernosum to block the norepinephrine signaling that keeps cavernosal smooth muscle in its default contracted state. The result is improved baseline blood flow and firmer, more reliable erections — typically lasting three to six months per treatment.[10][11]
Unlike apomorphine, the mechanism is local, the safety profile is well characterized, and the effect is continuous rather than on-demand. Combined with PDE5 inhibitors, response rates exceed those of either approach alone.[10][12]
3. Other established options
For men who don’t respond to oral or in-clinic options, intracavernosal injection therapy (alprostadil, Trimix), intraurethral alprostadil, vacuum erection devices, and penile prosthesis remain proven. Low-intensity shockwave therapy is increasingly studied for vascular ED. Restorative therapies (PRP, stem cell) remain experimental and unstandardized.
Considering a modern alternative?
If oral medications haven’t given you the firmness or reliability you want, UroFirm intracavernosal botulinum toxin is a published, in-clinic treatment with a 3–6 month effect.
When to consider what
For most men presenting with ED today, the decision pathway is clearer than it was when apomorphine was first studied:
- Mild-to-moderate ED, no contraindications: start with a PDE5 inhibitor. Try at least two different agents at full dose before declaring nonresponse.
- Inadequate response to PDE5: consider in-clinic options. Intracavernosal botulinum toxin and intracavernosal injection therapy are both reasonable; the choice depends on patient preference, anatomy, and goals.
- Severe vascular or neurogenic ED: intracavernosal injections, vacuum devices, or prosthesis. Combination therapy is often more effective than monotherapy.
Apomorphine’s place in this hierarchy is, today, vanishingly small. It is neither more effective nor better tolerated than the alternatives.
Frequently asked questions
Why was apomorphine pulled from the US market?
TAP Pharmaceuticals withdrew its New Drug Application in June 2000 after the FDA raised concerns about hypotension and syncope events in clinical trials.[3] Sublingual apomorphine was never approved for sale in the US.
Can I get apomorphine for ED from an online pharmacy?
You can find products marketed this way, but caution is warranted. Apomorphine is not FDA-approved for ED in the US, products from unregulated sources can be counterfeit or misrepresented, and unsupervised use carries syncope risk. Talk to a urologist about evidence-based alternatives instead.
Is apomorphine safer than Viagra?
No. Apomorphine has a higher rate of nausea, dizziness, and syncope than PDE5 inhibitors at therapeutic doses.[5] PDE5 inhibitors have over 25 years of post-market safety data and are generally well tolerated.
What’s the modern equivalent of apomorphine for ED?
There isn’t a direct equivalent — no centrally-acting agent has succeeded where apomorphine failed. The treatments that have actually advanced ED care since 2000 act peripherally: tadalafil’s long-window dosing (2003)[7] and once-daily option (2008)[8], avanafil’s faster onset (2012)[9], and intracavernosal botulinum toxin, which delivers months of benefit per treatment.[10]
Bottom line
Apomorphine for ED is a useful case study in how a clever mechanism doesn’t always translate into a better drug. Acting centrally to initiate an erection sounded elegant; in practice the side-effect ceiling was lower than the efficacy ceiling, and a peripheral approach won the market.
For a man considering treatment today, apomorphine isn’t a meaningful option in the US. The choice is between optimized PDE5 therapy, in-clinic options like UroFirm intracavernosal botulinum toxin, and — for those who don’t respond — established second-line therapies. Each has clearer evidence, better tolerability, and broader availability than apomorphine ever achieved.
References
- Heaton JP. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev. 2000;24(5):561–569.
- Heaton JP, Morales A, Adams MA, Johnston B, el-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology. 1995;45(2):200–206.
- Heaton JP, Adams MA. Update on central function relevant to sex: remodeling the basis of drug treatments for sex and the brain. Int J Impot Res. 2003;15 Suppl 5:S25–S32. (Reviews the US regulatory outcome of sublingual apomorphine, including the June 2000 NDA withdrawal by TAP Pharmaceuticals following FDA Advisory Committee concerns about hypotension and syncope.)
- European Medicines Agency. Uprima (apomorphine hydrochloride) — European Public Assessment Report. First marketing authorization 25 May 2001; subsequently withdrawn from the EU market.
- Dula E, Bukofzer S, Perdok R, George M; Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001;39(5):558–564.
- Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA; Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338(20):1397–1404.
- Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62(1):121–125.
- US Food and Drug Administration. Cialis (tadalafil) once-daily dosing approval, NDA 21-368 supplement. January 2008.
- US Food and Drug Administration. Stendra (avanafil) NDA 202-276 approval. April 27, 2012.
- El-Shaer W, Ghanem H, Diab T, Abo-Taleb A, Kandeel W. Intra-cavernous injection of BOTOX (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: randomized controlled trial. Andrology. 2021;9(4):1166–1175.
- Ghanem H, Raheem AA, AbdelRahman IF, et al. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6(1):135–142.
- Giuliano F, Denys P, Joussain C. Effectiveness and safety of intracavernosal IncobotulinumtoxinA (Xeomin) 100 U as an add-on therapy to standard pharmacological treatment for difficult-to-treat erectile dysfunction: a case series. Toxins (Basel). 2022;14(5):286.